Skip to main content
Top
Published in: BMC Medicine 1/2005

Open Access 01-12-2005 | Research article

Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population

Authors: Luis A García Rodríguez, Antonio González-Pérez

Published in: BMC Medicine | Issue 1/2005

Login to get access

Abstract

Background

Recent data indicate that chronic use of coxibs leads to an increased occurrence of thrombotic cardiovascular events. This raises the question as to whether traditional non-steroidal anti-inflammatory drugs (tNSAIDs) might also produce similar hazards. Our aim has been to evaluate the association between the chronic use of tNSAIDs and the risk of myocardial infarction (MI) in patients.

Methods

We performed a nested case-control analysis with 4,975 cases of acute MI and 20,000 controls, frequency matched to cases by age, sex, and calendar year.

Results

Overall, current use of tNSAID was not associated with an increased risk of MI (RR:1.07;95%CI: 0.95–1.21). However, we found that the relative risk (RR) of MI for durations of tNSAID treatment of >1 year was 1.21 (95% CI, 1.00–1.48). The corresponding RR was 1.34 (95% CI, 1.06–1.70) for non-fatal MI. The effect was independent from dose. The small risk associated with long-term use of tNSAIDs was observed among patients not taking low-dose aspirin (RR: 1.29; 95% CI, 1.01–1.65). The effect of long-term use for individual tNSAIDs ranged from a RR of 0.87 (95% CI, 0.47–1.62) with naproxen to 1.38 (95% CI, 1.00–1.90) with diclofenac.

Conclusion

This study adds support to the hypothesis that chronic treatment with some tNSAIDs is associated with a small increased risk of non-fatal MI. Our data are consistent with a substantial variability in cardiovascular risks between individual tNSAIDs.
Appendix
Available only for authorised users
Literature
1.
go back to reference FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004, 351 (17): 1709-1711. 10.1056/NEJMp048288.CrossRefPubMed FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med. 2004, 351 (17): 1709-1711. 10.1056/NEJMp048288.CrossRefPubMed
3.
go back to reference Solomon SD, McMurray JJ, Pfeffer MA, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005, 352: 1071-1080. 10.1056/NEJMoa050405.CrossRefPubMed Solomon SD, McMurray JJ, Pfeffer MA, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005, 352: 1071-1080. 10.1056/NEJMoa050405.CrossRefPubMed
4.
go back to reference Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of Rofecoxib, Celecoxib, and Other NSAIDs. Arch Int Med. 2005, 165: 978-984. 10.1001/archinte.165.9.978.CrossRef Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of Rofecoxib, Celecoxib, and Other NSAIDs. Arch Int Med. 2005, 165: 978-984. 10.1001/archinte.165.9.978.CrossRef
5.
go back to reference Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005, 330: 1366-1372. 10.1136/bmj.330.7504.1366.CrossRefPubMedPubMedCentral Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005, 330: 1366-1372. 10.1136/bmj.330.7504.1366.CrossRefPubMedPubMedCentral
6.
go back to reference García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A: Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation. 2004, 109: 3000-3006. 10.1161/01.CIR.0000132491.96623.04.CrossRefPubMed García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A: Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation. 2004, 109: 3000-3006. 10.1161/01.CIR.0000132491.96623.04.CrossRefPubMed
7.
go back to reference Walker AM: Observation and inference. An introduction to the methods of epidemiology. 1991, Newton Lower Falls: Epidemiology Resources Inc Walker AM: Observation and inference. An introduction to the methods of epidemiology. 1991, Newton Lower Falls: Epidemiology Resources Inc
8.
go back to reference García Rodríguez LA, Varas C, Patrono C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology. 2000, 11: 382-387. 10.1097/00001648-200007000-00004.CrossRefPubMed García Rodríguez LA, Varas C, Patrono C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology. 2000, 11: 382-387. 10.1097/00001648-200007000-00004.CrossRefPubMed
9.
go back to reference Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005, 365: 475-481.CrossRefPubMed Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005, 365: 475-481.CrossRefPubMed
10.
go back to reference Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004, 109: 1468-1471. 10.1161/01.CIR.0000124715.27937.78.CrossRefPubMed Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004, 109: 1468-1471. 10.1161/01.CIR.0000124715.27937.78.CrossRefPubMed
11.
go back to reference Reilly IA, FitzGerald GA: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987, 69: 180-186.PubMed Reilly IA, FitzGerald GA: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987, 69: 180-186.PubMed
12.
go back to reference Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001, 345: 1809-1817. 10.1056/NEJMoa003199.CrossRefPubMed Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001, 345: 1809-1817. 10.1056/NEJMoa003199.CrossRefPubMed
Metadata
Title
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population
Authors
Luis A García Rodríguez
Antonio González-Pérez
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2005
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-3-17

Other articles of this Issue 1/2005

BMC Medicine 1/2005 Go to the issue